|Bid||38.69 x 2000|
|Ask||38.70 x 1800|
|Day's Range||38.63 - 38.82|
|52 Week Range||37.20 - 44.54|
|PE Ratio (TTM)||43.57|
|Dividend & Yield||1.99 (5.12%)|
|1y Target Est||N/A|
Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ...
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
The drug would be the first such treatment in Europe.